KaloBios Pharmaceuticals (KBIO) Stock Skyrockets, CEO Will Stop Lending Shares - TheStreet

NEW YORK (TheStreet) -- KaloBios Pharmaceuticals (KBIO)  stock is spiking by 33.31% to $35.50 in morning trading Friday after CEO Martin Shkreli tweeted on Thursday that he would stop lending stock to people hoping to short it. 

"I spoke with my counsel & advisers and decided to stop lending my KBIO shares out until I better understand the advantages of doing so," Shkreli tweeted yesterday.

About 49% of KaloBios stock is short, MarketWatch reports.

To short a stock, an investor borrows it from someone who is long and later repurchases the shares. Short interest in a stock indicates that investors are betting that it will retreat further, so they can profit when they buy back shares at a lower price.

Those who have shorted KaloBios stock will attempt to cover their positions, giving Shkreli and others who are long an advantage, MarketWatch adds.

KaloBiosis a biopharmaceutical company based in San Francisco. 

Image placeholder title

KBIO

data by

YCharts

Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of Jim Cramer, TheStreet or any of its contributors.